Health
Trial: No Need to Stop RAS Inhibitors in COVID-19 – MedPage Today
REPLACE COVID trial supports findings from BRACE CORONA
Hospitalized COVID-19 patients may safely continue taking their angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the small REPLACE COVID trial.
The study’s primary hierarchical endpoint — a global rank score in which patients were ranked by the severity of their COVID disease course according to various biomarkers and clinical events, with a lower rank score meaning more severe COVID-19 hospitalization — was about the same whether people were…
-
General10 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Business18 hours agoBell Potter names the best ASX shares to buy in October
-
Noosa News22 hours agoResilience features in Sunshine Coast Open House
-
Noosa News17 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025